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Abstract
Background: Preclinical studies have evaluated haptoglobin (Hp) polymers from pooled human plasma as a
therapeutic protein to attenuate toxic effects of cell-free hemoglobin (Hb). Proof of concept studies have
demonstrated efficacy of Hp in hemolysis associated with transfusion and sickle cell anemia. However, phenotype-
specific Hp products might be desirable to exploit phenotype specific activities of Hp 1–1 versus Hp 2–2, offering
opportunities for recombinant therapeutics. Prohaptoglobin (proHp) is the primary translation product of the Hp
mRNA. ProHp is proteolytically cleaved by complement C1r subcomponent-like protein (C1r-LP) in the endoplasmic
reticulum. Two main allelic Hp variants, HP1 and HP2 exist. The larger HP2 is considered to be the ancestor variant
of all human Hp alleles and is characterized by an α2-chain, which contains an extra cysteine residue that pairs with
additional α-chains generating multimers with molecular weights of 200–900 kDa. The two human HP1 alleles
(HP1F and HP1S) differ by a two-amino-acid substitution polymorphism within the α-chain and are derived from
HP2 by recurring exon deletions.
Results: In the present study, we describe a process for the production of recombinant phenotype specific Hp
polymers in mammalian FS293F cells. This approach demonstrates that efficient expression of mature and fully
functional protein products requires co-expression of active C1r-LP. The functional characterization of our proteins,
which included monomer/polymer distribution, binding affinities as well as NO-sparing and antioxidant functions,
demonstrated that C1r-LP-processed recombinant Hp demonstrates equal protective functions as plasma derived
Hp in vitro as well as in animal studies.
Conclusions: We present a recombinant production process for fully functional phenotype-specific Hp therapeutics.
The proposed process could accelerate the development of Hb scavengers to treat patients with cell-free Hb
associated disease states, such as sickle cell disease and other hemolytic conditions.
* Correspondence: Dominik.Schaer@usz.ch
1Division of Internal Medicine, University Hospital Zurich, Ramistrasse 100,
CH-8091 Zurich, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schaer et al. BMC Biotechnology  (2018) 18:15 
https://doi.org/10.1186/s12896-018-0424-3
Background
Haptoglobin (Hp) is an abundant plasma protein, which
is primarily synthesized in the liver [1]. It is a high
affinity scavenger for free hemoglobin (Hb) that is occa-
sionally released from erythrocytes during hemolysis.
The complex that is formed between the two proteins
(Hb:Hp complex) provides a number of protective activ-
ities, which attenuate the toxic impact of free Hb in the
kidney, the vasculature and in surrounding tissues
accessible to free Hb [2–4]. The protection provided by
Hp attenuates two main toxicological consequences of
Hb. First, the large molecular size of the Hb:Hp complex
prevents extravasation of free Hb [5]. This mechanism
protects renal function and preserves vascular nitric
oxide (NO) homeostasis by limiting access of free Hb
into the vascular wall [6]. Secondly, Hb:Hp complex
formation stabilizes the structure of the Hb molecule in
a way that limits transfer of heme from its globin chains
to proteins and reactive lipids [7–10]. These mecha-
nisms are largely responsible for Hp’s anti-oxidative
function during hemolysis.
Cell free Hb is increasingly recognized as an amplifier of
disease in hemolytic anemias [11, 12]. While endogenous
Hp could principally provide significant protection against
free Hb toxicity, it is rapidly consumed and depleted during
more pronounced acute or prolonged hemolysis [13]. Re-
placement of Hp has therefore being considered as a thera-
peutic modality demonstrating preclinical proof-of-concept
in vitro and in animal models of hemolysis [14–18]. So far,
preclinical studies have evaluated Hp purified from pooled
human plasma fractions. However, this approach may
present relevant limitations in clinical translation, including;
(1) the mixture of different Hp phenotypes (1–1, 2–1 and
2–2) may trigger neutralizing antibody responses in some
patients during prolonged replacement therapy, (2) differ-
ing phenotypes may afford differing efficacy and (3) pheno-
typic forms may demonstrate different pharmacokinetics.
Considering the potential limitations of plasma de-
rived Hp, recombinant protein production may offer a
relevant strategy for production. Additionally, recom-
binant protein-production strategies may also generate
therapeutics with enhanced functionality, bioavailabil-
ity and pharmacokinetics.
Prohaptoglobin (proHp) is the primary translation prod-
uct of the Hp mRNA. In the endoplasmic reticulum proHp
dimerizes via disulfide bond formation and is proteolytically
cleaved by the protease complement C1r subcomponent-
like protein (C1r-LP) [19, 20]. As a result, Hp exists in most
mammals as a dimeric protein of 150 kDa consisting of two
light α-chains and two heavy β-chains that are linked by a
single disulfide bond (S-S) between the two α-chains, yield-
ing Hp 1–1 (Fig. 1) [21]. Interactions with Hb and the
clearance receptor CD163 are mediated by the larger and
more accessible β-chain [21]. In humans there exist two
main allelic Hp variants, HP1 and HP2. According to more
recent genetic analyses the larger HP2 is now considered to
be the ancestor variant of all human Hp alleles [22]. The
HP2 variant is characterized by an α2-chain, which contains
an extra cysteine residue that pairs with an additional α-
chain leading to the formation of a heterogeneous mixture
of multimers with molecular weights of 200–900 kDa (Hp
2–2). The two human HP1 alleles (HP1F and HP1S), which
differ by a minor two-amino-acid substitution polymorph-
ism within the α-chain, derived from HP2 by recurring
exon deletions. There exist no known functional differences
between these two HP1 variants.
In the present study, we describe a process for the
production of recombinant phenotype specific Hp pro-
teins. We demonstrate that efficient expression of ma-
ture and fully functional Hp in mammalian cells requires
co-expression of active C1r-LP.
Methods
Materials
Throughout this article, molar quantities of Hb relate to
total heme, which is equivalent to the single chain sub-
units of Hb (α- or β-chain). For the scavenger proteins
(Hpx and Hp), we considered one mole as the binding
capacity equivalent for one mole of heme, considering that
one Hp-αβ-subunit (≈ 42 kDa) can bind two heme mole-
cules (corresponding to one αβ-dimer). Hb concentration
was measured by spectrophotometry using a molar extinc-
tion coefficient of 524.3 M− 1 cm− 1 at an absorbance
wavelength of 414 nm (for oxyHb). MetHb or ferric Hb
(Fe3+), respectively, was generated by incubating oxyHb
(Fe2+) with a five times molar excess of K3[Fe (CN)6] in
PBS, pH 7.45 at room temperature for 10 min followed by
removal of K3[Fe (CN)6] by size exclusion chromatog-
raphy on a PD-10 column (GE Healthcare). Ferric Hb
concentration and complete oxidation to ferric iron (Fe3+)
within Hb where then determined by spectrophotometry.
Human plasma derived Hp (predominantly phenotype 2–
2) and Hpx were provided by CSL Behring (Bern,
Switzerland). Reconstituted lipoprotein (rLP; CSL-111)
was obtained from CSL Behring (Switzerland). rLP was
reconstituted in PBS to a final stock concentration of
40 g/L and immediately aliquoted and stored at − 80 °C
until use. For rLP, all given concentrations are relative to
the apoA1-lipoprotein concentration. The lipoprotein is
composed of human plasma derived apoA1 lipoprotein
and lecithin with phosphatidylcholine as the principal lipid
component.
Generation of cDNA expression plasmids
In humans Hp exists in two allelic forms; Hp1 and Hp2
(Hp2FS, longer isoform, Genbank Accession number
NP_005134.1), which differ only in their respective α-
chains. The Hp1 allele can be further subdivided into
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Hp1F (Genbank Accession number NP_001305067.1,
Asp52, Lys53) and Hp1S (Genbank Accession number
NP_001119574.1 Asn52, Glu53). Human Haptoglobin
cDNAs were codon-optimized for human expression
and synthesized by Geneart (Invitrogen™, Thermo
Fisher Scientific) each with a Kozak consensus se-
quence (GCCACC) immediately upstream of the initi-
ating methionine (+ 1). C-terminal 8× Histidine-tags
were fused in-frame using standard PCR-based muta-
genesis techniques. Once each cDNA was completed,
it was digested with NheI and XhoI and ligated into
pcDNA3.1 (Invitrogen™, Thermo Fisher Scientific). Transi-
ent transfections of expression plasmids using FS293F
cells were performed using 293fectin™ transfection reagent
(Invitrogen™, Thermo Fisher Scientific). To generate com-
pletely processed Hp1F, Hp1S and Hp2FS proteins cDNAs
encoding these proteins were co-transfected with a
cDNA (comprising 5% of the total DNA in the trans-
fection reaction) encoding human complement C1r
subcomponent-like protein (C1r-LP, Genbank Accession
number NP_057630), which mediates the proteolytic
cleavage of haptoglobin in the endoplasmic reticulum,
a
b
c
Fig. 1 Haptoglobin structure. a Schematic representation of Hp1 and Hp2. The common α-chain sequence of Hp1 and Hp2 is green. The blue
colored amino acid sequence within the α-chain of Hp2 determines the distinct molecular phenotypes. This sequence corresponds to exons 3
and 4 of the ancestral HP2 allele and was deleted due to non-allelic homologous recombination during the structural evolution of HP2 to HP1.
The cysteine residues that participate in protein multimerization are marked with a purple star. Both Hp1 and Hp2 further segregate into subtypes
S and F or FS and SS, respectively, based onto two base mutations at positions 52 and 53 or 111 and 112. The C1r-LP cleavage sites with the red
colored two base substitution sites in the mutated rHp are marked with black arrows. b Dimerization and proteolytic C1r-LP cleavage of pro-Hp 1
to Hp 1–1 dimer. c Protein quaternary structure of the Hp 1–1 homo-dimer with one inter-α-chain disulfide bond and three variants of Hp 2–2
cyclic homo-multimers with two inter-α-disulfide bonds
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with a FLAG (DYKDDDDK) epitope tag encoded at its C-
terminus. Uncleaved Hp, also known as Zonulin was
generated by alanine mutagenesis of the C1r-LP cleavage
sites in Human Hp1S at Q101 and R102, and Human
Hp2FS at Q160 and R161.
Purification of recombinant Haptoglobin variants
Purification of recombinant Hp variants was performed by
two-step chromatography using an ÄKTA Express system
(GE Healthcare Bio-Sciences, PA, USA) equipped with
1 mL HisTrap columns (GE Healthcare Bio-Sciences, PA,
USA) followed by size exclusion chromatography (SEC)
on a 16/60 Superdex 200 column (GE Healthcare Bio-
Sciences, PA, USA) equilibrated with PBS. Hp-containing
fractions were pooled and concentrated using Amicon
Ultra-15 centrifugal filter units (Merck-Millipore, MS,
USA) according to the manufacturer’s protocol. The con-
centration of purified recombinant proteins was measured
by OD280 on a Trinean DropSense96 system (Trinean,
Gentbrugge, Belgium) and purity of the concentrates was
verified by SDS-PAGE (NuPAGE system, Thermo Fisher
Scientific, MA, USA).
Surface plasmon resonance (SPR) and size exclusion
chromatography
Surface plasmon resonance (SPR) measurements were
performed on a ProteOn XPR36 instrument (Bio-Rad,
Reinach, Switzerland). Hp was immobilized on a Pro-
teOn Sensor Chip GLM using standard amine coupling
chemistry. The running buffer was 150 mM NaCl,
10 mM HEPES (pH 7.6), 3 mM EDTA and 0.05% (v/v)
polysorbate 20 at + 25 °C. Sensograms were interspot
referenced and kinetic analysis performed by globally fit-
ting the corrected data to a Langmuir 1:1 binding model
using the manufacturers software (ProteOn Manager Soft-
ware 3.1.0.6). For size-exclusion chromatography (HPLC)
mixture of purified Hb and Hp variants or plasma samples
were separated on an analytical BioSep-SEC-S3000 (600 ×
7.5 mm) column (Phenomenex, Torrance, CA) attached
to a Waters 2535 quatrinary gradient module, Waters
2998 photodiode array multi-wavelength detector, and
controlled using Empower Pro software (Waters Corp.,
Milford, MA). The mobile phase was 50 mM Potassium
Phosphate, pH 7.4. The absorption wavelengths were set
at λ = 280 nm, λ = 405 and 413 nm to detect heme in
protein.
Vascular function studies
Vascular function studies were performed as described
elsewhere [5]. In short, rings (approx. 7 mm in length)
of porcine left anterior descending coronary arteries
(LAD) were prepared and mounted under 40 mN resting
tension, via two stainless steel hooks, in a 10 mL organ
bath containing prewarmed (37 °C) and aerated (95% O2
and 5% CO2) Krebs-Henseleit Solution (118 mM NaCl,
4.7 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.2 mM
KH2PO4, 25 mM NaHCO3, 11 mM glucose, pH ad-
justed to 7.4). Measurement of isometric tension via a
force displacement transducer (Biegestab K30, Hugo
Sachs Elektronik – Harvard Apparatus GmbH, 29,232,
March, Germany) was digitally recorded. As precon-
tracting agent, prostaglandin F2α (PGF2α; Sigma, Buchs,
Switzerland) was used at a 10 μM concentration and ni-
tric oxide synthase was irreversible inhibited by L-N5-
(1-Iminoethyl)-ornithine hydrochloride (L-NIO; Sigma)
at a 10 μM concentration. 30 nM of the extracellular
NO donor MAHMA-NONOate (ENZO Life Sciences,
Lausen, Switzerland) were injected into the immersion
buffer to induce a transient and short-lived NO-
mediated dilatory response of the PGF2α precontracted
porcine coronary artery segments. Hb and all other
compounds were used in concentrations indicated in the
figure legends. Hp was always used in 1.2 M excess rela-
tive to Hb. The recorded vascular function responses
were normalized relative to the 40 mN baseline tension
(= 100%) and the maximal PGF2α contraction (= 0%).
Responses in the plots are therefore indicated as [%
PGF2α]. Normalized segments were subsequently plot-
ted (mean ± SEM) and analyzed in GraphPad Prism
Software Version 5.0.
Animal experiments
All animal studies were approved by the FDA Institutional
Animal Care and Use Committee, with all experimental
procedures performed in adherence to the NIH guidelines
on the use of experimental animals. Male Hartley Guinea
Pigs weighing 300–400 g were obtained from Charles
Rivers Laboratories (Wilmington, MA) and acclimated
upon arrival at the FDA animal care facility (The Federal
Research facility at White Oak, Silver Spring, MD). For
Hb and Hp administration and systemic arterial blood
pressure recordings indwelling, fluid-filled catheters were
placed into the jugular vein and carotid artery, respect-
ively. Animals were dosed with 25 mg (~ 1552 mmol) of
human Hb in saline (0.3 mL total volume) to establish a
maximum MAP response. At 5 min post Hb dosing rHp
1–1 or rHp 2–2 was administered at a Hb equimolar dose
via an intravenous (i.v., jugular) infusion to guinea pigs (n
= 4) to evaluate the blood pressure response post Hb and
rHp dosing and to perform blood collection for determin-
ation of Hb complexation with rHps in plasma. Systemic
blood pressure and heart rate was measured from the in-
dwelling carotid catheter using a Gould P23XL pressure
transducer (Becton Dickinson, Singapore) connected to a
Transonic Powerlab 4/30 (Transonic Systems, Ithaca,
New York). Blood pressure and heart rate were measured
at baseline (30 min), after Hb infusion (5 min) and for
30 min post rHp 1–1 or rHp 2–2. Plasma (0.1 mL) was
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collected at baseline, 5 min post Hb infusion and 5,
30 min and 60 min post rHp dosing to establish the
percent of Hb bound to Hp.
Hemopexin capture assay
Heme release from metHb (Fe3+) was measured using a
hemopexin capture assay that was described earlier [23].
The transfer of heme to Hpx was measured as gradual
disappearance of the characteristic metHb (Fe3+) UV-
VIS spectrum and an increase of the spectrum that is
specific for the heme-Hpx complex. Reactions were
measured with a Cary 60 UV-VIS spectrophotometer
(Agilent Technologies, Switzerland). Experiments were
conducted in 1 mL semi-micro cuvettes at 37 °C and
absorbance was measured over time at every 2 nm be-
tween 350 and 650 nm with a 0.025 s integration time
per wavelength and time-point. The concentrations
over time were calculated by multicomponent spectral
deconvolution against standard extinction curves of
HbFe3+ and heme-Hpx using a non-negative least squares
algorithm.
Lipoprotein peroxidation
Experiments were conducted in 1 mL semi-micro cu-
vettes at 37 °C using a Cary 60 spectrophotometer
(Agilent, Switzerland). Absorbance was measured over
time at every 2 nm between 350 to 650 nm with a
0.025 s integration time per wavelength and timepoint.
Spectra were deconvoluted against standard extinction
curves of oxyHb (Fe2+), deoxyHb (Fe2+) and metHb (Fe3+)
using a non-negative least squares algorithm. The time to
oxygen depletion was calculated as the minimum of the
first derivative of the oxyHb concentration over time [7].
Cell culture experiments
Human umbilical vein endothelial cells (HUVEC) were
obtained from Lonza (Switzerland) and cultured in EGM
medium (Lonza) under standard conditions. All experi-
ments were conducted in complete EGM without ascor-
bic acid with cells forming a confluent monolayer.
Fluorescence microscopy
HUVEC cells were grown on sterile, round 12-mm glass
coverslips (Hecht-Assistent, Sondheim, Germany) coated
with rat-tail collagen (BD Biosciences, San Jose, CA,
USA) in 24-cluster wells. After treatment, cells were
washed with PBS, pH 7.4 (Sigma Chemical Co.), fixed
with 2.5% paraformaldehyde in PBS for 15 min and
permeabilized with 0.1% Triton X-100 (Sigma Chemical
Co.) in PBS for 5 min at room temperature. After wash-
ing, nonspecific binding sites were blocked with 10%
goat serum and 1% bovine serum albumin (Sigma
Chemical Co.) in PBS for 1 h at room temperature.
Adherens junction protein staining was performed with
a polyclonal rabbit anti-human β-catenin antibody (Cell
Signaling Technology, Danvers, MA, USA) overnight at
4 °C at a dilution of 1: 50 in PBS with 1% goat serum
and 0.1% bovine serum albumin. As a secondary anti-
body a Cy3-labeled polyclonal sheep anti-rabbit anti-
body (IgG fraction; Abcam, Cambridge, UK) was used
at a dilution of 1:50. Nuclear counterstaining was per-
formed with 10 μg/mL 4,6-diamidino-2-phenylindole
(DAPI; Sigma Chemical Co.). After washing, coverslips
were mounted with ProLong Gold antifade reagent-
mounting medium (Molecular Probes, Invitrogen, Eugene,
OR, USA) and visualized using a Zeiss Observer.Z1 with a
Colibri.2 and ApoTome.2 system (Carl Zeiss AG,
Feldbach, Switzerland) at a 400 times original optical
magnification.
Electrical cell impedance sensing (ECIS)
Confluent HUVEC cells grown in 10-cm tissue culture
plates were trypsinized and plated into 8W10E+ ECIS
plates filled with 400 μL medium per well. After 24 h,
the medium was changed to 300 μL per well. After
stabilization of the ECIS signal, 100 μL of the 4× reac-
tion mixture was added directly to the cells while
recording the electrical cell impedance at 4 kHz on an ECIS
Z Theta instrument (ibidi GmbH, Planegg/Martinsried,
Germany) with ECIS software version 1.2.52. After signal
normalization (mean pre-experimental signal), the amount
of time required to lose endothelial monolayer integrity
was calculated by finding the minimum in the first deriva-
tive of the measured resistance over time.
Results
Co-expression of C1r-LP is required for efficient produc-
tion of mature haptoglobin in mammalian cells
Overexpression of recombinant Hp in FS293F cells in
the absence of sufficient C1r-LP is not optimal because
it results in a significant amount of uncleaved proHp.
Figure 2a shows a Coomassie-stained reducing SDS-
PAGE of unpurified recombinant Hp produced in
FS293F cells. The left image shows secreted Hp 1–1 pro-
duced by rHP1S transfected cells. The right image shows
rHp 2–2 produced by rHP2FS transfected cells. In
addition to some cleaved Hp α- (12 and 19 kDa) and β-
(47 kDa) chains a larger uncleaved protein correspond-
ing to uncleaved proHp (53 and 57 kDa) is present. To
overcome the problem of inefficient proHp processing
in FS293F cells we have co-expressed Hp with the cleav-
age protease C1r-LP, similar to the C1r-LP coexpression
in COS-1 cells in an earlier study [20]. Figure 2b shows
a Coomassie stained gel (left image) and an anti-8His
Western blot (right image) of secreted Hp1S, which was
produced with (right lane) and without (left lane) C1r-
LP co-expression. With C1r-LP co-expression proHp is
entirely cleaved resulting in mature Hp consisting of
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α- and β-chains. Since for this experiment C1r-LP was
expressed as an 8-His tagged protein the protease can
also be visualized at 68 kDa. The recombinant Hps
produced by this strategy are glycosylated, although
with a different glycan pattern compared to plasma de-
rived Hp as determined by HPLC-ESI-MS. The glycan
analysis data are shown in the Additional file 1.
C1r-LP cleaves proHp after arginine R102 (P-V-Q-R ↓)
in Hp1F and Hp1S or after R161 in Hp2FS (Fig. 1a). To
understand the functional importance of Hp maturation,
we have produced recombinant Hp variants with amino-
acid substitutions within the predicted cleavage site of
Hp1S (Q101A, R102A) and Hp2FS (Q160A, R161A). The
Coomassie-stained gel shown in Fig. 2c confirms that the
two cleavage-site mutated Hp variants remain uncleaved
as indicated by the absence of the α-chain subunit under
reducing conditions. However, subunit crosslinking and
multimerization appear to be unaffected in uncleaved Hp.
Under non-reducing conditions wild-type and mutant Hp
variants have an identical appearance as a single (α1β)2
dimer band of 114–116 kDa in case of Hp 1–1 and a
series of (α2β)n multimers in case of Hp 2–2.
C1r-LP processing of Hp is mandatory for high affinity Hb
binding and irreversible complex formation
We have measured the Hb-binding kinetics of rHp by sur-
face plasmon resonance (SPR). Figure 3 shows association
and dissociation signal curves of a concentration range of
Hb run against immobilized Hp. Immobilized plasma de-
rived Hp of mixed phenotype and human albumin were
used as positive and negative controls (Fig. 3a). Plasma
derived Hp and the C1r-LP processed Hps (rHp1S and
rHp2FS) show an identical Hb binding pattern with rapid
association and hardly detectable dissociation, which is
typical for the irreversible complex formation between the
two proteins. In contrast, the cleavage-site mutated Hp
variants (rHp1Smut and rHp2FSmut) show a lower affinity
reversible Hb-binding, which was nevertheless significant
compared to the completely absent binding of Hb to
immobilized albumin. Rates of complex formation (ka)
and dissociation (kd) are listed in Fig. 3c. The equilibrium
constant KD was calculated from the two kinetic constants
through the defining relation KD = kd/ka.
The SPR derived binding properties are supported by
size-exclusion chromatography analyses of equimolar
mixtures of Hb with the different rHp variants (Fig. 3b).
Wild-type and mutant rHp do both resolve Hb:Hp
complexes as the main fraction, indicating that even
uncleaved rHp forms low-affinity complexes with Hb.
However with rHp1Smut and rHp2FSmut there appears
also a significant peak of free Hb in addition to the lar-
ger Hb:Hp complex fraction. This indicates that the low
affinity reversible Hb binding of these proteins results in
an equilibrium of complex and unbound Hp and Hb,
respectively.
Recombinant haptoglobin preserves vascular nitric oxide
signaling in vitro and in vivo
Preservation of arterial nitric oxide (NO) signaling is a
key function of Hp, which directly relates to the protein’s
capacity to sequester Hb in a Hb:Hp complex. The large
complex cannot extravasate and does therefore not ac-
cess subendothelial vascular sites of NO production and
signaling. To explore the functional activity of recombin-
ant Hp proteins and, more specifically, the requirement
of Hp subunit cleavage in vascular protection, we mea-
sured how the different rHp proteins could revert the
a b
c
Fig. 2 Haptoglobin and C1r-LP co-expression in FS293F cells.
a Coomassie stained reducing SDS-PAGE of rHp1S and rHp2FS
produced in transfected FS293F cells. Hp α-chain appears at 12
or 19 kDa and Hp β-chain appears at 47 kDa. Additionally
uncleaved proHp1 and proHp2 appear at their expected size of
53 or 57 kDa. b With co-expression of C1r-LP (+) all proHp is
efficiently cleaved into its subunits. C1r-LP appears at 68 kDa.
The right image shows an anti-8His Western blot, which shows
uncleaved proHp in the absence of C1r-LP and smaller Hp β-
chain as well as the His-tagged protease in the presence of
C1r-LP co-expression. c The Coomassie stained gel of reduced
protein samples (left side) illustrates that the cleavage-site
mutated (mut) Hp variants remain uncleaved and appear as
single proHp bands at their expected size. With non-reduced
protein samples polymers of Hp 1–1 and Hp 2–2 can be
resolved in wild-type as well as in mutated variants
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ab
c
Fig. 3 (See legend on next page.)
Schaer et al. BMC Biotechnology  (2018) 18:15 Page 7 of 13
disruptive activity of cell-free Hb on NO mediated arter-
ial relaxation. Rings of porcine coronary arteries show a
transient dilatory response after addition of the short-
lived NO donor MAHMA-NONOate (Fig. 4a and b,
green line). This dilatory response was completely
blunted in the presence of cell-free Hb (32 μM) (Fig. 4b,
red line). Plasma derived Hp completely restored the
dilatory activity of NO when present in a ≥ 1:1 M
concentration relative to Hb (Fig. 4b, blue line). The
recombinant Hp rHp1F, rHp1S and rHp2FS demon-
strated protective effects that were comparable to the
effects of plasma-derived Hp (Fig. 4c and e). In con-
trast, the cleavage-site mutated Hp variants rHp1Smut
and rHp2FSmut only partially restored arterial NO re-
sponses (Fig. 4d and e), indicating that the irreversible
high-affinity Hb binding is critical for the NO preserv-
ing function of Hp. A summary and statistical compari-
son of all rHp effects expressed as area under the curve
(AUC) of the dilatory responses is shown in Fig. 4e.
In vivo the protection of NO signaling by Hp trans-
lates into a hemodynamic stabilization during Hb infu-
sion. When guinea pigs were infused with a bolus of
25 mg oxyHb a rapid increase in mean arterial blood
pressure (MAP) could be observed (Fig. 5a), which was
associated with the appearance of cell-free Hb in plasma
(Fig. 5b). Injection of 25 mg rHp1S or rHp2FS at the
time of peak blood pressure immediately eliminated free
Hb in plasma to undetectable levels, while blood pres-
sure declined to baseline. After injection of rHp all the
Hb absorbance signal could be detected within the large
molecular size Hb:Hp complex fractions, which ap-
peared as a monomeric signal after rHp1S treatment or
as a multimeric signal after rHp2FS treatment. When
saline or albumin were infused instead of rHp blood
pressure remained around peak levels for up to 1 hour,
additionally, rHp 1–1 and rHp 2–2 administered in ab-
sence of Hb showed no effect on blood pressure or heart
rate after repeat dosing (data not shown).
rHp prevents heme release and lipid peroxidation
Heme release from metHb (Fe3+) is a surrogate marker
of the oxidant capacity of Hb and can be measured as
heme transfer in a reaction mixture of metHb (Fe3+)
with the high affinity heme-scavenger protein hemo-
pexin (Hpx), which exerts a specific absorption spectrum
as heme-hemopexin complex. Plasma derived Hp as well
(See figure on previous page.)
Fig. 3 Hb-binding activity of plasma derived and recombinant Hp. a Human plasma derived Hp (left) or albumin (right) were immobilized on the
SPR-Chip and tested for Hb-binding activity by surface plasmon resonance (SPR). The lines represent the association and dissociation signal curves
of a range of Hb concentrations in the fluid-phase (0, 312.5, 625, 1250, 2500 and 5000 nM). b SPR analyses of rHp variants with (mut) and
without cleavage-site mutations (left panels) with the corresponding size exclusion HPLC chromatographs (right panels). The blue lines represent
the signals of the Hb + rHp mixtures, the red line shows the signal of Hb alone. All size exclusion HPLC traces are scaled identically to fit to the
red Hb peak chromatogram. c Association (ka), dissociation (kd) and equilibrium (KD) constants for the SPR experiments
a b
c
e
d
Fig. 4 Vascular nitric oxide (NO) signaling. a Schematic illustration of the
experimental setup. Porcine coronary artery segments were mounted
under 40 mN resting tension in an organ bath and pre-contracted with
PGF2α (= baseline). NO-mediated dilatory responses were recorded after
injection of the NO donor MAHMA-NONOate (30 nM) into the
immersion buffer. b Hb (32 μM) but not Hb complexes with
predominantly human plasma derived (pd) Hp 2–2 blunted the
dilatory response. c and d Wild-type rHp variants preserved
vascular NO-signaling comparable to plasma derived Hp. In
contrast, intermediate dilatory responses were observed in the
presence Hb mixed with cleavage site mutated rHp variants. The
traces show mean +/− SEM of at least 6 averaged responses
recorded in three independent experiments. e ANOVA statistics
of the AUCs of the dilatory responses recorded in the different
experiments. Non-overlapping circles indicate significantly
different responses at p < 0.05 (Tukey-Kramer post-test)
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as rHp1F, rHp1S and rHp2FS completely blocked heme-
transfer. In contrast the cleavage site mutated rHp variants
rHp1Smut and rHp2FSmut only partially impaired transfer
of heme from metHb (Fe3+) to hemopexin (Fig. 6a).
One potential pathway of oxidative Hb toxicity relates
to the oxidation of lipoproteins by cell-free Hb, which
may result in the generation of toxic lipid oxidation
products. We have recently described a kinetic assay
which measures oxygen consumption as a surrogate
marker of lipid peroxidation in the reaction of oxyHb
with a reconstituted lipoprotein (rLP). In this assay,
spectrophotometric detection of oxygen desaturation of
Hb (oxyHb (Fe2+) ➔ deoxyHb (Fe2+)) is used as a
reaction-intrinsic sensor for oxygen depletion in an air-
tight system. Figure 6b shows that oxygen becomes
depleted around 10 min after start of a reaction with
10 μM of oxyHb and 0.5 g/L rLP. In contrast in the
presence of equimolar concentrations of plasma derived
a
b
Fig. 5 Blood pressure control and in vivo Hb:Hp complex formation. a Guinea pigs (n = 4 per group) were infused with 25 mg of Hb at time
0 min. At t = 5 min, when mean arterial blood pressure (MAP) reached a maximum increase rHp (25 mg) was injected. Separate groups were
treated with rHp1S (left) and rHp2FS (right). Data show mean ± SD. Values were compared with an ANOVA for repeated measures and a Tukey
post-hoc test correction for multiple comparisons. b Plasma samples collected at baseline, 5 min post Hb infusion and 5, 30 and 60 min post rHp
injection were analyzed by HPLC size-exclusion chromatography. The red area indicates the elution profile of a cell-free Hb standard, the blue area
indicates the elution profile of the respective Hb:Hp complexes with rHp1S and rHp2FS
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Hp or rHp1F, rHp1S or rHp2FS no oxygen depletion
could be observed even after > 6 h, indicating that these
proteins fully interrupt lipid peroxidation by Hp. In con-
trast, cleavage-site mutated rHp variants did not provide
any significant (anti-oxidant) protection in this assay.
Biologic toxicity resulting from cell-free Hb triggered
lipid peroxidation can also be measured in an in vitro
cell culture assay using the disruption of endothelial
monolayer integrity as an endpoint. Fluorescence mi-
croscopy analyses of the distribution of the junctional
protein β-catenin indicate that the in-situ reaction of
10 μM Hb (Fe2+) and 0.5 g/L rLP caused disruption of
monolayer integrity within 24 h after addition of the
reactants to the cell culture medium (Fig. 6c). In con-
trast, when recombinant rHp1S or rHp2FS were also
added at equimolar concentration to the reaction the
a
c
d e
b
Fig. 6 rHp prevents heme release and lipid peroxidation. a Heme transfer from metHb to hemopexin was measured by spectrophotometry in a
reaction mixture of 10 μM metHb(Fe3+) and 10 μM hemopexin. Plasma derived (pd) and recombinant wild-type Hp at 10 μM concentration
completely blocked the reaction while only partial inhibition was observed with the cleavage site mutated rHps (green lines). b Lipoprotein
peroxidation was measured by spectrophotometry as a function of oxyHb deoxygenation in a reaction mixture of 10 μM oxyHb(Fe2+) with
0.5 g/L rLP. The graph shows the time to anoxia. Peroxidation was completely blocked for > 6 h by the plasma derived and recombinant wild-
type Hps, whereas lipid oxidation was not delayed compared to free Hb by the cleavage-site mutated rHp variants rHp1Smut and rHp2FSmut.
c The identical lipid peroxidation reaction of rLP (0.5 g/L) and oxyHb (10 μM) as described in (b) was performed in cultures of HUVEC cells.
Toxicity of lipid peroxidation products was monitored by fluorescence microscopy of β-catenin (yellow) and nuclear morphology (DAPI, blue) at
24 h after initiation of the reaction (original optical magnification 400×). Identical experiments as in (c) were performed on HUVEC monolayers
monitored in an ECIS instrument. d Shows original electrical monolayer resistance data over time of biologic replicates. The colors represent the
different treatments as indicated in (e). e “Time to monolayer breakdown” was calculated as a derivative from the electrical resistance data shown
in (d). Data indicates mean ± SD of 6 biologic replicates
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endpoint was not reached. Cleavage-site mutated rHp1Smut
and rHp2FSmut did not visually alter β-catenin distribution
compared to the experiments performed in the absence of
Hp. Figure 6d shows raw ECIS transendothelial resistance
measurement traces of individual replicates of HUVEC
monolayers incubated with rLP alone (black lines), rLP +
Hb (Fe2+) (red lines) or rLP +Hb + different Hp variants
(green, purple and black lines). Figure 6e shows the pooled
first derivative data of these traces, which indicate an
estimate for the time-point of monolayer breakdown.
The data confirm the morphologic data demonstrating
complete monolayer protection with the wild-type
rHp1s and rHp2FS (black) and minimal, though statisti-
cally significant, protection with cleavage site mutated
Hps (green and purple).
Discussion
Haptoglobin is a candidate therapeutic protein for dis-
eases that are caused or amplified by the pathophysio-
logical effects of cell-free Hb [11]. Among the potential
indications for Hp are the hereditary hemolytic anemias
such as sickle cell disease, procedure-related hemolysis
during open heart surgery or subarachnoid hemorrhage.
So far, human pooled plasma has been used as the
source for experimental Hp products and one plasma-
derived Hp product is approved and marketed in Japan
since 1984. While the use of these products appears to
be safe and effective in several preclinical disease models
and in patients with acute hemolysis, recombinant pro-
duction processes for Hp may offer several advantages,
which may enhance the properties of plasma derived Hp
in therapeutic applications.
Two exons of the Hp exhibit copy number variations
that affect Hp protein structure and multimerization
patterns. The distribution of the different phenotypes
varies across populations worldwide depending upon
racial origin. The allelic prevalence of HP1 for example
approaches about 0.07 in parts of south Asia with in-
creasing occurrence north- and westwards up to 0.7 in
parts of west Africa and South America. This results in a
phenotype distribution of dimeric Hp 1–1, hetero-
multimeric Hp 2–1 and homo-multimeric Hp 2–2 of
roughly 0.1, 0.4 and 0.5 in Asia, 0.15, 0.5 and 0.35 in Eur-
ope/North America, 0.3, 0.35 and 0.15 in Africa (0.2
anhaptoglobinemic) and 0.5, 0.4 and 0.1 in South America
[24]. Pooled human plasma derived Hp is therefore largely
composed of multimeric protein species. Although the
antioxidant and vascular NO-sparing functions of Hp 1–1
and Hp 2–2 appear to be comparable if examined in vitro
or in animal studies investigating short-term therapeutic
end-points [23], several epidemiologic studies suggest that
Hp 2–2 may be associated with inferior cardiovascular
outcomes [25–27]. A large genome-wide association study
(GWAS) in more than 20′000 individuals found that the
Hp exonic deletions characteristic of Hp 1–1 are associ-
ated with lower plasma total and LDL cholesterol concen-
trations [22, 28]. The observation that lower cholesterol
was found in individuals with both genotypes (HP1F and
HP1S), which were present in considerably different SNP
haplotypes, suggest that cholesterol levels are related to
structural Hp variation rather than nearby polymorphisms
in unrelated genes. It is unclear so far whether the benefi-
cial effects of Hp 1–1 (or the adverse effects of Hp 2–2)
on cholesterol metabolism could be transferred by pheno-
type specific therapy. However, the concept should be
considered in anticipated clinical trials exploring the
effects of chronic Hp supplementation in patients with
hemolysis. The availability of recombinant phenotype
specific therapeutics may support such trials. Recombin-
ant technology may also allow targeted modification of
the Hp protein to enhance functionality or pharmacoki-
netic properties such as bioavailability and clearance of
the Hb:rHp complexes by the macrophage CD163 scaven-
ger receptor system.
Hp is a large glycoprotein that undergoes complex
posttranslational modifications, such as disulfide-bridge
multimerization and cleavage of proHp [19, 20]. The
functional relevance of this modification, which ultim-
ately produces a hetero-multimeric protein composed of
α- and β-subunits remained unclear. In our studies, we
established a production process, which is based on co-
expression of proHp with its cleavage protease C1r-Lp.
We observed that co-expression of the two proteins
dramatically enhanced production efficiency and almost
entirely eliminated the generation of immature protein.
This effect was equally effective for all tested genetic Hp
variants, indicating that both rHp 1–1 and rHp 2–2
could be produced using this approach. rHp 1–1 and
rHp 2–2 produced by this process appeared fully func-
tional, when compared with plasma derived human Hp.
rHp formed irreversible complexes with cell-free Hb in
vitro and in vivo, it preserved vascular NO signaling in
the presence of Hb in porcine coronary arteries and ab-
rogated the acute hypertensive effect of cell-free Hb in
rats. rHp was also equal to plasma-derived Hp in
preventing heme-release from metHb and in blocking
lipoprotein oxidation by oxyHb.
We have also explored the functional demand for
proHp processing by C1r-LP. For these experiments, we
expressed variants of Hp1S and Hp2FS with targeted
mutations in their respective C1r-LP cleavage site. The
introduced amino acid substitutions completely pre-
vented segregation of α- and β-chains, yielding unpro-
cessed proHp for functional studies. Compared to the
mature protein, unprocessed Hp demonstrated revers-
ible Hb binding and incomplete complex formation with
a considerable fraction of free Hb even when excess rHp
was present. Accordingly, unprocessed Hp only partially
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protected vascular NO-signaling and it was less effective
in preventing heme release from metHb compared to
plasma-derived Hp and mature rHp. Interestingly, the
mutated Hp variants were weak inhibitors of Hb trig-
gered lipoprotein oxidation, suggesting that the irrevers-
ible high affinity complex formation between Hb and Hp
are an absolute requirement for its antioxidant function
and it might, in part, be this function of Hp which has
driven the evolution of one of strongest protein-protein
interactions found in nature. While our results establish
that high affinity and irreversible binding between Hp
and Hb are an absolute requirement for Hp’s protective
activity against Hb toxicity, our studies cannot definitely
define the role of C1r-LP processing in the “functional
maturation” of the protein. The peptide chain mutations
that we introduced to prevent proHp cleavage could the-
oretically reduce Hb-binding affinity through introduc-
tion of additional conformational deteriorations in the
protein. In fact, other authors found that recombinant,
mainly uncleaved Hp expressed in COS cells demon-
strated considerable Hb binding activity [29].
Conclusion
We provide evidence that the high affinity, irreversible
complex formation between Hp and Hb is essential for
Hp’s functions in the detoxification of free Hb. The pro-
posed production process of fully functional and
phenotype-specific recombinant Hp could accelerate the
development of Hb scavengers to treat patients with
cell-free Hb associated disease states, such as sickle cell
disease and other hemolytic conditions.
Additional file
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μm, 2.1 x 150 mm column using an acetonitrile / 50mM ammonium
formate gradient with fluorescence detection. Table S1. Peak area by
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